tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CollPlant Biotechnologies Reports Positive Non-Clinical Results for Regenerative Filler

Story Highlights
  • CollPlant Biotechnologies announced positive results from non-clinical studies of its regenerative dermal filler.
  • The company plans to advance the filler into clinical trials, marking a significant milestone in aesthetic medicine.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CollPlant Biotechnologies Reports Positive Non-Clinical Results for Regenerative Filler

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Collplant Holdings ( (CLGN) ) has provided an update.

On September 30, 2025, CollPlant Biotechnologies announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler. This product, which combines hyaluronic acid with a modified form of rhCollagen, is designed to offer both immediate and long-lasting benefits in aesthetic medicine. The successful completion of these studies marks a significant milestone for CollPlant as it prepares to advance the filler into clinical trials, potentially redefining standards in aesthetic treatments by integrating contouring precision, structural support, and tissue regeneration.

The most recent analyst rating on (CLGN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

Spark’s Take on CLGN Stock

According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.

Collplant Holdings’ overall stock score is primarily impacted by its weak financial performance, characterized by significant revenue declines and negative cash flow. While technical indicators show some positive momentum, the negative P/E ratio and lack of dividend yield present valuation challenges. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on CLGN stock, click here.

More about Collplant Holdings

CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative solutions using its proprietary non-animal recombinant human collagen (rhCollagen). The company operates in the fields of 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, with products designed to address various indications within these areas.

Average Trading Volume: 41,497

Technical Sentiment Signal: Sell

Current Market Cap: $39.29M

For a thorough assessment of CLGN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1